Welcome to our dedicated page for Satsuma Pharmaceuticals news (Ticker: STSA), a resource for investors and traders seeking the latest updates and insights on Satsuma Pharmaceuticals stock.
Satsuma Pharmaceuticals, Inc. (STSA) generates news primarily around the development, clinical evaluation, and regulatory review of STS101, its dihydroergotamine (DHE) nasal powder product candidate for the acute treatment of migraine. As a clinical- and late-stage biopharmaceutical company and a wholly owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), Satsuma’s updates often center on neurology-focused drug development and drug-device combination technology.
News coverage for Satsuma commonly includes announcements of Phase 3 clinical trial results from the SUMMIT efficacy study and the ASCEND long-term, open-label safety study, as well as analyses of sustained efficacy, safety, tolerability, and patient impressions of STS101. Releases describe endpoints such as freedom from pain, freedom from the most bothersome symptom, and long-term nasal safety, along with exploratory efficacy data and patient-reported ease of use.
Regulatory milestones are another key theme. Satsuma has reported the submission of a New Drug Application for STS101 to the U.S. Food and Drug Administration under the 505(b)(2) pathway and the FDA’s acceptance of that NDA for review. News items also cover scientific visibility for STS101, including oral and poster presentations at meetings such as the American Headache Society Annual Scientific Meeting and the American Academy of Neurology Annual Meeting.
Corporate developments feature prominently as well, including Satsuma’s agreement to be acquired by SNBL and subsequent references to Satsuma as a wholly owned subsidiary. Readers following STSA news can expect updates on clinical data, regulatory interactions, scientific conference presentations, and corporate transactions related to STS101 and its associated branded product Atzumi™. Bookmarking this page can help track how the STS101 program and Satsuma’s role within SNBL’s intranasal drug delivery platform evolve over time.
Satsuma Pharmaceuticals (Nasdaq: STSA) announced that CEO John Kollins will present at several upcoming conferences in September 2020. The events include:
- H.C. Wainwright 22nd Annual Global Investment Conference on September 15 at 4:00 PM ET
- Cantor Fitzgerald Virtual Global Healthcare Conference on September 16 at 1:20 PM ET
- Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 17 at 4:15 PM ET
Links to webcasts of the presentations will be available on their investor webpage. The company is developing STS101, a potential treatment for migraines.
Satsuma Pharmaceuticals (STSA) announced the completion of the EMERGE Phase 3 efficacy trial for STS101, preparing to report top-line results by early October 2020. They initiated the ASCEND Phase 3 open-label safety trial aiming to enroll 300 migraine patients. Financially, Satsuma reported a net loss of $11.3 million for Q2 2020, with cash reserves of $93.7 million expected to sustain operations through 2021. R&D expenses rose to $8.8 million, attributed to increased trial activities, while general administrative expenses also saw a significant uptick.
Satsuma Pharmaceuticals (Nasdaq: STSA) has initiated patient enrollment in the ASCEND trial, a Phase 3 open-label study assessing the safety and tolerability of STS101 (dihydroergotamine nasal powder) for acute migraine treatment. The trial aims to enroll up to 300 subjects, evaluating long-term safety and efficacy. Results are expected to support a New Drug Application filing in Q4 2021, alongside data from the EMERGE trial. This study marks a significant step in developing STS101 as a potential treatment for migraine sufferers.
Satsuma Pharmaceuticals (STSA) appointed Thomas M. Soloway to its Board of Directors effective July 2, 2020. Soloway, an industry veteran with extensive operational and financial expertise, currently serves as Executive Vice President and COO of Audentes Therapeutics. His experience is expected to advance Satsuma during Phase 3 development and prepare for the commercialization of STS101, a novel treatment for acute migraines. The company anticipates topline results from the EMERGE Phase 3 trial in the second half of 2020, positioning STS101 as a significant player in migraine therapeutics.
Satsuma Pharmaceuticals (Nasdaq: STSA) has announced that its two poster presentations on the efficacy and safety of dihydroergotamine (DHE) for treating migraines will be showcased at the American Headache Society’s Annual Scientific Meeting, starting June 13, 2020. The posters, titled Safety of Dihydroergotamine for the Acute Treatment of Migraine: Reality vs Perception and The Efficacy of Dihydroergotamine versus Emerging Acute Migraine Medications, will be accessible on Satsuma's website. The company is developing STS101, a novel nasal delivery system for DHE, currently in Phase 3 clinical trials.
Satsuma Pharmaceuticals (Nasdaq: STSA) announced the completion of enrollment for its pivotal Phase 3 EMERGE trial of STS101, a nasal powder formulation of dihydroergotamine for migraine treatment. The trial, involving over 1,140 patients across 121 sites, aims to demonstrate STS101's efficacy and safety. The company is set to report topline results in the second half of the year, with plans to initiate a second Phase 3 trial (ASCEND) in Q3 2020. If successful, data from both trials could support a New Drug Application by late 2021.
Satsuma Pharmaceuticals (Nasdaq: STSA) has announced that CEO John Kollins will present at the Jefferies Virtual Healthcare Conference on June 3, 2020, at 1:00 p.m. ET. The presentation will be accessible via a live audio webcast on the company’s website, with a replay available for 90 days after. The conference will feature over 400 healthcare companies and discussions on investment opportunities within the industry. Satsuma is developing STS101, a novel treatment for migraines, currently in Phase 3 development.
Satsuma Pharmaceuticals announced that two abstracts from its development program for STS101, an intranasal Dihydroergotamine (DHE) formulation, have been selected for presentation at the 2020 AAN Annual Meeting. The presentations focus on the pharmacokinetic comparison of STS101 with other DHE formulations and the effectiveness of a water-insoluble mucoadhesive formulation for rapid drug absorption. STS101, currently in Phase 3 development, promises to offer a non-injectable, easy-to-use option for migraine treatment if approved.
Satsuma Pharmaceuticals (Nasdaq: STSA) has announced that its STS101 EMERGE Phase 3 efficacy trial is on track, with topline data expected in the second half of 2020. Despite the COVID-19 pandemic, the company reports no significant delays in program timelines. As of Q1 2020, Satsuma had cash and equivalents totaling $104.1 million, offering sufficient runway through a planned NDA filing by the end of 2021. The company reported a net loss of $11.8 million for Q1 2020, with increased R&D expenses attributed to ongoing clinical trials and operational costs.
Summary not available.